PDCD1LG2 and melanoma: The two cell lines (BN-SKCM-01 and BN-SKCM-03) that did not respond to IFN-γ treatment with PD-L2 upregulation showed a higher PD-L2 promotor methylation than IFN-γ responsive melanoma cell lines.